Now, this is what we understand to be the FDA preferred method of horizontal correction. What we find is that that procedure can detect 25 percent differences but cannot detect 12.5 percent differences.
The next method we looked at, 7-day half-life, it's about the same. There's a little bit of improvement in the point estimate but still not very good.
The day minus 1 correction method actually does a little bit better. The point estimate is migrating toward the real value and the confidence interval now contains the true value.
And last, the TSH method that takes into account TSH suppression does even better, and a new thing appears in the statistic in that the difference now becomes statistically significant between those two doses.
Now, at this point, let me just focus on a couple of things that have already been mentioned before with a couple of the other speakers.
First, looking at the confidence intervals, they're quite narrow, and as was mentioned before, this is a narrow therapeutic margin drug. So with such low variability and narrow confidence intervals, do we really